Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer

Status:
Recruiting

Trial end date:
2027-06-01

Target enrollment:

Participant gender:

This study is a prospective, open-label, phase II clinical study for patients with HR+/HER2- advanced breast cancer.

Phase 2

Fudan University

Apatinib
Fulvestrant